Evaluation of Diagnostic Value in Using a Panel of Multiple Tumor-Associated Antigens for Immunodiagnosis of Cancer

Table 1

Frequency of antibodies to eight TAAs.

Autoantibodies to	Number (%) of autoantibodies in different types of cancers
	Lung (98)	HCC (50)	Colorectal (46)	Gastric (41)	Others (69)	Total (304)	NHS (58)
Koc	9 (9.2)^a	9 (18.0)^b	7 (15.2)^b	2 (4.9)	8 (11.6)^a	35 (11.5)^b	0
p62	15 (15.3)^b	10 (20.0)^b	10 (21.7)^b	4 (9.8)	9 (13.0)^a	48 (15.8)^b	1 (1.7)
Imp1	17 (17.3)^b	8 (16.0)^b	10 (21.7)^b	6 (14.6)^b	9 (13.0)^a	50 (16.4)^b	0
Cyclin B1	17 (17.3)^b	10 (20.0)^b	8 (17.4)^a	11 (26.8)^b	12 (17.4)^b	58 (19.1)^b	1 (1.7)
p16	18 (18.4)^b	3 (6.0)	9 (19.6)^a	4 (9.8)	13 (18.8)^b	47 (15.5)^a	2 (3.4)
Survivin	19 (19.4)^b	6 (12.0)	7 (15.2)^a	6 (14.6)^a	10 (14.5)^a	48 (15.5)^b	1 (1.7)
C-myc	24 (24.5)^b	7 (14.0)	10 (21.7)^b	7 (17.1)^a	17 (24.6)^b	65 (21.4)^b	2 (3.4)
p53	25 (25.5)^b	10 (20.0)^a	11 (23.9)^b	5 (12.2)	14 (20.3)^b	65 (21.4)^b	2 (3.4)
Cumulative to eight antigens	63 (64.3)^b	33 (66.0)^b	30 (65.2)^b	23 (56.1)^b	44 (63.8)^b	193 (63.5)^b	8 (13.8)

Cutoff value: mean +2 SD of NHS; P values to NHS were calculated to be <0.05 (^a) or 0.01 (^b).
HCC: hepatocellular carcinoma; NHS: normal human sera.